![]() |
市场调查报告书
商品编码
1744659
2032 年手术勒除器市场预测:按产品类型、圈套类型、材料、技术、应用、最终用户和地区进行的全球分析Surgical Snare Market Forecasts to 2032 - Global Analysis By Product Type (Reusable Surgical Snares and Single-use (Disposable) Surgical Snares), Loop Type, Material, Technology, Application, End User and By Geography |
根据 Stratistics MRC 的数据,全球手术勒除器市场预计在 2025 年达到 19 亿美元,到 2032 年将达到 28 亿美元,预测期内的复合年增长率为 5.8%。
手术勒除器是用于微创手术的专用医疗设备,用于移除、取回和操作体内组织。它们由柔性线圈组成,通常由不銹钢或合成材料製成。透过手柄操作,它们可以牢固地抓住并切除息肉、病变和其他异常生长物。手术勒除器常用于内视镜手术,能够精确、可控制地移除组织,同时最大限度地减少创伤、缩短恢復时间,并提高临床手术效率。
根据世界卫生组织统计,癌症是全球第一位死因,全球约有1,000万人死于癌症。其中,最常见的癌症类型是乳癌,约有226万例;其次是肺癌,约有221万例;最后是大肠癌,约有193万例。
慢性病增多
在全球范围内,大肠直肠癌、发炎性肠道疾病和胃肠道息肉等慢性疾病的负担日益加重,大大推动了对外科勒除器的需求。由于这些疾病通常需要内视镜介入诊断和治疗,外科勒除器已成为息肉切除和组织取样的必需工具。慢性疾病的激增也推动了外科勒除器器的普及,并给医疗保健系统施加了采用微创手术的压力。
先进手术勒除器高成本
手术勒除器的製造和采购成本通常较高,因为它们采用了强化材料、符合人体工学的设计,或具备可旋转尖端等创新功能。小型诊所和医疗机构可能难以投资这些工具,因此可能会选择较少、成本较低的替代品。此外,报销挑战和预算限制也进一步加剧了先进手术设备的采购难度。
拓展尚未开发的新兴市场
新兴经济体快速的都市化、医疗基础设施的改善以及人们对胃肠道健康的日益关注,为市场成长提供了巨大的机会。拉丁美洲、东南亚和中东部分地区等地区的医疗保健投资和内视镜中心的建立正在增加。随着这些地区医疗旅游业的发展,预计对勒除器等微创手术器材的需求将会增加,进一步提升市场渗透率和品牌知名度。
严格的报销政策
保险限制和复杂的核准流程可能会阻碍医院投资高成本的内视镜工具。此外,不同地区不同的报销政策也造成了市场准入的不一致。随着政府和保险公司越来越重视具有成本效益的治疗方法,製造商必须克服监管障碍,以确保其产品得到广泛应用,从而阻碍市场成长。
新冠疫情扰乱了外科勒除器器市场,影响了供应链,并减缓了择期手术的发展。由于医院优先考虑急诊,内视镜手术的需求暂时下降。然而,随着医疗体系的调整,市场逐渐復苏,这得益于对微创手术的日益重视,以减少住院时间和感染风险。疫情也加速了技术进步,促使製造商开发更有效率、更具成本效益的外科勒除器,以满足不断变化的医疗保健需求。
可重复使用手术勒除器市场预计将在预测期内成长至最大
可重复使用手术勒除器器预计将在预测期内占据最大市场占有率,这得益于其成本效益和在临床环境中的长期可用性。越来越多的医疗机构采用可重复使用产品,以降低营运成本并减少医疗废弃物。这些勒除器通常更受医院的青睐,因为医院的重复手术使用量较大,重复使用更经济。
预计预测期内冷勒除器部分将达到最高复合年增长率
预计冷勒除器细分市场将在预测期内实现最高成长率,因为它无需使用电烧即可切除小息肉。对于出血性疾病患者和服用抗凝血剂的患者而言,此方法安全可靠,因为它降低了对周围组织造成热损伤的风险。此外,由于操作简便,可以在门诊进行,这也有助于提高冷圈套器的采用率。
在预测期内,亚太地区预计将占据最大的市场占有率,这得益于人口快速增长、胃肠道疾病患病率上升以及人们对癌症早期发现意识的不断提升。中国、印度和日本等国家正在增加对医疗基础设施的投资,尤其是在内视镜技术。政府的筛检计画和促进早期诊断的倡议也进一步推动了手术勒除器的普及。
预计北美地区在预测期内的复合年增长率最高。这得归功于内视镜手术的持续进步和微创技术的广泛应用。该地区拥有许多优势,例如成熟的医疗设备产业、健全的报销制度以及结直肠癌的高发生率,而结直肠癌是勒除器切除术的主要适应症之一。持续的技术创新和主要参与者雄厚的研发资金投入也推动了该地区的快速成长。
According to Stratistics MRC, the Global Surgical Snare Market is accounted for $1.9 billion in 2025 and is expected to reach $2.8 billion by 2032 growing at a CAGR of 5.8% during the forecast period. Surgical snare is a specialized medical device used in minimally invasive procedures to excise, retrieve, or manipulate tissue within the body. It consists of a flexible wire loop, often made of stainless steel or synthetic materials, which are controlled by a handle to securely grasp and cut polyps, lesions, or other abnormal growths. Commonly used in endoscopic surgeries, surgical snares enable precise and controlled removal of tissue while minimizing trauma, reducing recovery time, and enhancing procedural efficiency in clinical settings.
According to WHO, cancer is the leading cause of death, accounting for nearly 10 million deaths worldwide. The most common type of cancer was breast cancer, accounting for nearly 2.26 million cases, followed by lung and colon cancer, accounting for approximately 2.21 and 1.93 million cases, respectively.
Increasing prevalence of chronic diseases
The growing global burden of chronic diseases such as colorectal cancer, inflammatory bowel disease, and gastrointestinal polyps is significantly boosting the demand for surgical snares. As these conditions often require endoscopic interventions for diagnosis and treatment, the use of surgical snares becomes critical for polyp removal and tissue sampling. Thus this surge in chronic illnesses places pressure on healthcare systems to adopt minimally invasive procedures are fueling the adoption of surgical snares.
High cost of advanced surgical snares
Surgical snares incorporate enhanced materials, ergonomic designs, or innovative features like rotatable tips, tend to be expensive to manufacture and procure. Smaller clinics and healthcare facilities may find it difficult to invest in these tools, opting instead for lower-cost alternatives with fewer capabilities. Additionally, reimbursement challenges and budget constraints further complicate the procurement of advanced surgical equipment.
Expansion into untapped emerging markets
Rapid urbanization, improving healthcare infrastructure, and increasing awareness of gastrointestinal health in emerging economies present substantial opportunities for market growth. Regions such as Latin America, Southeast Asia, and parts of the Middle East are experiencing an uptick in healthcare investments and the establishment of endoscopy centers. As medical tourism grows in these areas, demand for minimally invasive surgical tools like snares is expected to rise and facilitate deeper market penetration and brand recognition.
Strict reimbursement policies
Insurance limitations and complex approval processes can deter hospitals from investing in high-cost endoscopic tools. Additionally, variations in reimbursement policies across different regions create inconsistencies in market accessibility. As governments and insurers emphasize cost-effective treatment options, manufacturers must navigate regulatory hurdles to ensure broader adoption of their products hampering the growth of the market.
The COVID-19 pandemic disrupted the surgical snare market, affecting supply chains and delaying elective procedures. Hospitals prioritized emergency treatments, leading to a temporary decline in demand for endoscopic interventions. However, as healthcare systems adapted, the market rebounded with increased focus on minimally invasive surgeries to reduce hospital stays and infection risks. The pandemic also accelerated technological advancements, prompting manufacturers to develop more efficient and cost-effective surgical snares to meet evolving healthcare needs.
The reusable surgical snares segment is expected to be the largest during the forecast period
The reusable surgical snares segment is expected to account for the largest market share during the forecast period due to their cost-efficiency and long-term usability in clinical settings. Healthcare facilities are increasingly adopting reusable options to reduce operational expenses and minimize medical waste. These snares are often preferred in high-volume hospitals where repeated procedures make reuse more economical.
The cold snare segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the cold snare segment is predicted to witness the highest growth rate owing to their advantages in removing small polyps without the use of electrocautery. This method reduces the risk of thermal injury to surrounding tissues, making it safer for patients with bleeding disorders or those on anticoagulants. The simplicity of the technique also makes it accessible for outpatient procedures, contributing to its rising adoption.
During the forecast period, the Asia Pacific region is expected to hold the largest market share driven by a rapidly growing population, increasing prevalence of gastrointestinal diseases, and rising awareness about early cancer detection. Countries such as China, India, and Japan are seeing increased investments in healthcare infrastructure, particularly in endoscopic technology. Government screening programs and initiatives to promote early diagnosis are further driving the adoption of surgical snares.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR attributed to ongoing advancements in endoscopic procedures and robust adoption of minimally invasive technologies. The region benefits from a well-established medical device industry, favorable reimbursement systems, and a high prevalence of colorectal cancer, one of the primary indications for snare polypectomy. Continuous innovation by key market players and strong R&D funding also contribute to the rapid growth.
Key players in the market
Some of the key players in Surgical Snare Market include Zimmer Biomet Holdings, Inc., B. Braun Melsungen AG, Smith & Nephew PLC, FUJIFILM Holdings Corporation, Richard Wolf GmbH, Pentax Medical, Karl Storz SE & Co. KG, Stryker Corporation, Veran Medical Technologies (acquired by Boston Scientific), Sklar Surgical Instruments, Medtronic PLC, Olympus Corporation, Steris PLC, Boston Scientific Corporation, Merit Medical Systems, Inc., Avalign Technologies, Inc., Hill-Rom Holdings, CONMED Corporation, and Medline Industries.
In May 2025, Richard Wolf GmbH entered into an agreement with Photocure to develop a high-definition flexible blue light cystoscope for global commercialization.
In May 2025, Merit Medical Systems, Inc. acquired Biolife Delaware, L.L.C., aiming to enhance its product offerings and improve financial performance.
In April 2025, Zimmer Biomet Holdings, Inc. completed the acquisition of Paragon 28 for approximately $1.1 billion, enhancing its portfolio in foot and ankle surgical devices.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.